Lilly to offer higher-dose versions of weight-loss drug on website

Eli Lilly will offer the highest doses (12.5mg and 15mg) of its weight-loss drug Zepbound directly to cash-paying customers via its website starting in August, with prescriptions available from July 7. This move, offering all doses for $499/month or less, aims to expand access, compete with compounded versions, and capitalize on the potential $150 billion obesity drug market where Lilly has recently overtaken Novo Nordisk despite Novo's first-mover advantage.

Analysis

Eli Lilly is strategically expanding access to its popular weight-loss drug, Zepbound, by making the two highest doses (12.5mg and 15mg) available directly to cash-paying customers via its LillyDirect website from early August, with all approved doses priced at $499 per month or less. This direct-to-consumer (DTC) expansion, allowing prescriptions from July 7, aims to bolster Zepbound's market penetration and counter competition, particularly as recent prescription data indicates Lilly has overtaken Novo Nordisk in the potential $150 billion obesity drug market, despite Novo's first-mover advantage. The move is further supported by the U.S. Food and Drug Administration's recent ban on sales of compounded copies of these drugs, which had proliferated during shortages. However, Lilly faces headwinds, exemplified by CVS Health's decision to remove Zepbound from certain reimbursement formularies effective July 1, favoring Novo Nordisk's Wegovy due to more advantageous pricing. Lilly's enhanced DTC strategy, including earlier price reductions on Zepbound vials, underscores its commitment to navigating a competitive landscape characterized by high demand and evolving payer dynamics to maximize its share of this lucrative market.

Key Decisions for Investors

• Investors should evaluate Eli Lilly's enhanced direct-to-consumer strategy for Zepbound, priced at $499 monthly, as a key driver for sales growth and market share consolidation, especially given its recent lead over Novo Nordisk.
• For Novo Nordisk, the intensified competition from Lilly's direct Zepbound sales and pricing, coupled with payer decisions like CVS favoring Wegovy on price, warrants close monitoring of its market share and strategic responses.
• Consideration should be given to the evolving dynamics of the $150 billion obesity drug market, where direct sales channels, payer leverage, and regulatory actions significantly influence competitive positioning and profitability for leading pharmaceutical companies.